Therapeutic implications of the hyperglutamatergic effects of NMDA antagonists

Neuropsychopharmacology

Volumn 21, Issue 6, 1999, Pages S143-S157

  Krystal, John H ^a,b,c   Beiger, Aysenil ^a,b   D’souza, D Cyril ^b   Anand, Amit ^a,b   Charney, Dennis S ^a,b,c   Aghajanian, George K ^a,b,c   Moghaddam, Bita ^a,b,c  

^a YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b VA CONNECTICUT HEALTHCARE SYSTEM   (United States)

^c Yale University School of Medicine and the Connecticut Mental Health Center   (United States)

Author keywords

5 HT2A; 907; Attention; Cognitive function; Frontal cortex; Glutamate; Ketamine; Lamotrigine; LY354740; M100907; MDL 100; NMDA; Pharmacotherapy; Schizophrenia; Serotonin

Indexed keywords

ALPHA (2,3 DIMETHOXYPHENYL) 1 [2 (4 FLUOROPHENYL)ETHYL] 4 PIPERIDINEMETHANOL; AMPHETAMINE; DOPAMINE; EGLUMETAD; GLUTAMIC ACID; HALOPERIDOL; KETAMINE; LAMOTRIGINE; N METHYL DEXTRO ASPARTIC ACID RECEPTOR BLOCKING AGENT; PHENCYCLIDINE; SEROTONIN; SEROTONIN 2A ANTAGONIST;

ARTICLE; COGNITIVE DEFECT; DOPAMINE RECEPTOR BLOCKING; HUMAN; NEUROTRANSMISSION; NONHUMAN; PATHOPHYSIOLOGY; PRIORITY JOURNAL; PYRAMIDAL NERVE CELL; SCHIZOPHRENIA;

EID: 0032785487     PISSN: 0893133X     EISSN: 1740634X     Source Type: Journal    
DOI: 10.1016/S0893-133X(99)00102-5     Document Type: Article

References (148)

1. Abi-Saab W, D’Souza DC, Moghaddam B, Krystal JH (1998): The NMDA antagonist model for schizophrenia: Promises and pitfalls. Pharmacopsychiatry 31:104-109
2. Adler CM, Malhotra AK, Goldberg T, Elman I, Pickar D, Breier A (1998): A comparison of ketamine-induced andschizophrenic thought disorder. Society of BiologicalPsychiatry, Fifty-third Annual Convention, pp 83S-84S
3. Aghajanian GK, Marek GJ (1997): Serotonin induces excita-tory postsynaptic potentials in apical dendrites of neo-cortical pyramidal cells. Neuropharmacology 36:589-599
4. Aghajanian GK, Marek GJ (1999): Serotonin model of schizo-phrenia: Emerging role of glutamate mechanisms. Brain Res Rev, in press
5. Akbarian S, Bunney WE Jr., Potkin SG, Wigal SB, Hagman JO, Sandman CA, Jones EG (1993): Altered distributionof nicotinamide-adenine dinucleotide phosphate-dia-phorase cells in frontal lobe of schizophrenics impliesdisturbances of cortical development. Arch Gen Psy-chiat 50:169-177
6. Akbarian S, Kim JJ, Potkin SG, Hagman JO, Tafazzoli A, Bunney WE Jr., Jones EG (1995): Gene expression forglutamic acid decarboxylase is reduced without loss ofneurons in prefrontal cortex of schizophrenics [see com-ments]. Arch Gen Psychiat 52:258-266; discussion 267-278
7. Allen RM, Young SJ (1978): Phencyclidine-induced psycho-sis. Am J Psychiat 135:1081-1084
8. Anand A, Charney DS, Cappiello A, Berman RM, Oren DA, Krystal JH (1997): Lamotrigine reduces the psychotomi-metic—but not the mood elevating—effects of ketaminein humans. Proceedings of the 36th Annual Meeting, American College of Neuropsychopharmacology, p 251
9. Andreasen NC, Arndt S, Alliger R, Miller D, Flaum M (1995): Symptoms of schizophrenia. Methods, mean-ings, and mechanisms. Arch Gen Psychiat 52:341-351
10. Anis NA, Berry SC, Burton NR, Lodge D (1983): The disso-ciativeanaesthetics, ketamine and phencyclidine, selec-tively reduce excitation of central mammalian neurones by N-methyl-aspartate. Br J Pharmacol 79:565-575
11. Arnsten AF (1997): Catecholamine regulation of the prefrontal cortex. J Psychopharmacol 11:151-162
12. Bagley J, Moghaddam B (1997): Temporal dynamics of glutamate efflux in the prefrontal cortex and in the hip-pocampus following repeated stress: Effects of pretreat-ment with saline or diazepam. Neuroscience 77:65-73
13. Bartha R, Williamson PC, Drost DJ, Malla A, Carr TJ, Cortese L, Canaran G, Rylett RJ, Neufeld RW (1997): Mea-surement of glutamate and glutamine in the medial prefrontal cortex of never-treated schizophrenic patientsand healthy controls by proton magnetic resonancespectroscopy. Arch Gen Psychiat 54:959-965
14. Belger A, Kirino E, McCarthy G, Gore JC, Krystal JH (1997): Assessment of prefrontal activation by infrequentvisual targets and nontarget novel stimuli in schizo-phrenia: A functional MRI study. Proceedings of the36th Annual Meeting, American College of Neuropsy-chopharmacology, p 190
15. Benes FM, McSparren J, Bird ED, San Giovanni JP, Vincent SL (1991): Deficits in small interneurons in prefrontaland cingulate cortices of schizophrenic and schizoaffec-tive patients. Arch Gen Psychiat 48:996-1001
16. Bjork A, Bergman I, Gustavsson G (1992): Amperozide in the treatment of schizophrenic patients: A preliminary report. In Meltzer HY (ed), Novel Antipsychotic Drugs. New York: Raven, pp 47-58
17. Boutros N, Belger A, D’Souza DC, Krystal JH (1999): Com-parison of four components of sensory gating in schizo-phrenia and healthy control subjects. Psychiat Res, in press
18. Braff D, Stone C, Callaway E, Geyer M, Glick I, Bali L (1978): Prestimulus effects on human startle reflex in normalsand schizophrenics. Psychophysiology 15:339-343
19. Breier A, Malhotra AK, Pinals DA, Weisenfeld NI, Pickar D (1997): Association of ketamine-induced psychosis withfocal activation of the prefrontal cortex in healthy vol-unteers. Am J Psychiat 154:805-811
20. Buchsbaum MS, Haier RJ, Potkin SG, Nuechterlein K, Bracha HS, Katz M, Lohr J, Wu J, Lottenberg S, JerabekPA, et al. (1992): Frontostriatal disorder of cerebralmetabolism in never-medicated schizophrenics. ArchGen Psychiat 49:935-942
21. Carlezon WA Jr., Wise RA (1996): Rewarding actions of phencyclidine and related drugs in nucleus accumbensshell and frontal cortex. J Neurosci 16:3112-3122
22. Carlsson A, Hansson LO, Waters N, Carlsson ML (1997): Neurotransmitter aberrations in schizophrenia: New perspectives and therapeutic implications. Life Sci 61:75-94
23. Carlsson M, Carlsson A (1990): Interactions between glutamatergic and monoaminergic systems within thebasal ganglia—Implications for schizophrenia and Par-kinson’s disease. TINS 13:272-276
24. Carpenter WT Jr., Heinrichs DW, Wagman AM (1988): Deficit and nondeficit forms of schizophrenia: The concept. Am J Psychiat 145:578-583
25. Cleghorn JM, Garnett ES, Nahmias C, Brown GM, Kaplan RD, Szechtman H, Szechtman B, Franco S, Dermer SW, Cook P (1990): Regional brain metabolism during audi-tory hallucinations in chronic schizophrenia. Br J Psy-chiat 157:562-570
26. Cleghorn JM, Garnett ES, Nahmias C, Firnau G, Brown GM, Kaplan R, Szechtman H, Szechtman B (1989): Increasedfrontal and reduced parietal glucose metabolism inacute untreated schizophrenia. Psychiat Res 28:119-133
27. Clow DW, Lee SJ, Hammer RP Jr. (1991): Competitive (AP7) and non-competitive (MK-801) NMDA receptor antago-nists differentially alter glucose utilization in rat cortex.Synapse 7:260-268
28. Conti F (1997): Localization of NMDA receptors in the cerebral cortex: A schematic overview. Brazil J Med Biol Res 30:555-560
29. Coyle JT (1996): The glutamatergic dysfunction hypothesis for schizophrenia. Harv Rev Psychiat 3:241-253
30. D’Souza DC, Gil R, Belger A, Zimmerman L, Tracy L, Larvey K, Cassello K, Krystal J (1997): Glycine-ket-amine interactions in healthy humans. Proceedings ofthe 36th Annual Meeting, American College of Neuro-psychopharmacology, p 286
31. Davidson M, Harvey PD, Powchik P, Parrella M, White L, Knobler HY, Losonczy MF, Keefe R S, Katz S, Frecska E(1995): Severity of symptoms in chronically institution-alized geriatric schizophrenic patients. Am J Psychiat152:197-207
32. deBrabander JM, Kramers RJ, Uylings HB (1998): Layer-spe-cific dendritic regression of pyramidal cells with aging in the human prefrontal cortex. Eur J Neurosci 10:1261-1269
33. Di Mascio A, Bernardo DL, Greenblatt DJ, Marder JE (1976): A controlled trial of amantadine in drug-inducedextrapyramidal disorders. Arch Gen Psychiat 33:599-602
34. Domino EF, Chodoff P, Corssen G (1965): Pharmacologic effects of CI-581, a new dissociative anesthetic, in man.Clin Pharm Ther 6:279-291
35. Fatemi SH, Sidwell R, Akhter P, Sedgewick J, Thuras P, Bailey K, Kist D (1998): Human influenza viral infectionin utero increases nNOS expression in hippocampi ofneonatal mice. Synapse 29:84-88
36. Fauman B, Aldinger G, Fauman M, Rosen P (1976): Psychiatric sequelae of phencyclidine abuse. ClinToxicol 9:529-538
37. Flaherty JA, Bellur SN (1981): Mental side effects of amantadine therapy: Its spectrum and characteristics in a normal population. J ClinPsychiat 42:344-345
38. Freedman LR, Rock D, Roberts SA, Cornblatt BA, Erlen-meyer-Kimling L (1998): The New York High-Risk Project: Attention, anhedonia, and social outcome.Schizophr Res 30:1-9
39. Freedman R, Adler LE, Myles-Worsley M, Nagamoto HT, Miller C, Kisley M, McRae K, Cawthra E, Waldo M(1996): Inhibitory gating of an evoked response torepeated auditory stimuli in schizophrenic and normalsubjects. Human recordings, computer simulation, andan animal model. Arch Gen Psychiat 53:1114-1121
40. Gage FH (1998): Stem cells of the central nervous system. CurrOpinNeurobiol 8:671-676
41. Ghoneim MM, Hinrichs JV, Mewaldt SP, Petersen RC (1985): Ketamine: behavioral effects of subanesthetic doses. JClinPsychopharmacol 5:70-77
42. Ghosh A, Carnahan J, Greenberg ME (1994): Requirement for BDNF in activity-dependent survival of cortical neurons. Science 263:1618-1623
43. Gleason SD, Shannon HE (1997): Blockade of phencyclidine-induced hyperlocomotion by olanzapine, clozapine, and serotonin receptor subtype selective antagonists inmice. Psychopharmacology 129:79-84
44. Goff DC, Tsai G, Levitt J, Amico E, Manoach D, Schoenfeld DA, Hayden DL, McCarley R, Coyle JT (1999): A pla-cebo-controlled trial of D-cycloserine added to conven-tional neuroleptics in patients with schizophrenia. ArchGen Psychiat 56:21-27
45. Goff DC, Tsai G, Manoach DS, Coyle JT (1995): Dose-finding trial of D-cycloserine added to neuroleptics for negativesymptoms in schizophrenia. Am J Psychiat 152:1213-1215
46. Goff DC, Tsai G, Manoach DS, Flood J, Darby DG, Coyle JT (1996): D-cycloserine added to clozapine for patientswith schizophrenia. Am J Psychiat 153:1628-1630
47. Goldman-Rakic PS, Lidow MS, Gallager DW (1990): Overlap of dopaminergic, adrenergic, and serotoninergic recep-tors and complementarity of their subtypes in primateprefrontal cortex. J Neurosci 10:2125-2138
48. Goldman-Rakic PS, Selemon LD (1997): Functional and ana-tomical aspects of prefrontal pathology in schizophrenia [see comments]. Schizophr Bull 23:437-458
49. Green SM, Johnson NE (1990): Ketamine sedation for pediatric procedures: Part 2, Review and implications. Ann Emerg Med 19:1033-1046
50. Grillon C, Courchesne E, Ameli R, Geyer MA, Braff DL (1990): Increased distractibility in schizophrenic patients.Electrophysiologic and behavioral evidence. Arch GenPsychiat 47:171-179
51. Groenewegen HJ, Wright CI, Uylings HB (1997): The ana-tomical relationships of the prefrontal cortex with lim-bic structures and the basal ganglia. J Psychopharmacol 11:99-106
52. Grossberg S (1984): Some normal and abnormal behavioral syndromes due to transmitter gating of opponent pro-cesses. BiolPsychiat 19:1075-1118
53. Grunze H, Greene RW, Moller HJ, Meyer T, Walden J (1998): Lamotrigine may limit pathological excitation in thehippocampus by modulating a transient potassium outward current. Brain Res 791:330-334
54. Grunze HC, Rainnie DG, Hasselmo ME, Barkai E, Hearn EF, McCarley RW, Greene RW (1996): NMDA-dependentmodulation of CA1 local circuit inhibition. J Neurosci16:2034-2043
55. Haas DA, Harper DG (1992): Ketamine: a review of its pharmacologic properties and use in ambulatory anesthesia. AnesthProg 39:61-68
56. Heresco-Levy U, Javitt DC, Ermilov M, Mordel C, Silipo G, Lichtenstein M (1999): Efficacy of high-dose glycine inthe treatment of enduring negative symptoms of schizo-phrenia. Arch Gen Psychiat 56:29-36
57. Jakab RL, Goldman-Rakic P, Leranth C (1997): Dual role of substance P/GABA axons in cortical neurotransmis-sion: synaptic triads on pyramidal cell spines and bas-ket-like innervation of layer II-III calbindin interneuronsin primate prefrontal cortex. Cereb Cortex 7:359-373
58. Jakab RL, Goldman-Rakic PS (1998): 5-Hydroxytryptamine2A serotonin receptors in the primate cerebral cortex: Possi-ble site of action of hallucinogenic and antipsychoticdrugs in pyramidal cell apical dendrites. Proc Nat AcadSci USA 95:735-740
59. Javitt DC, Sershen H, Hashim A, Lajtha A (1997): Reversal of phencyclidine-induced hyperactivity by glycine and theglycine uptake inhibitor glycyldodecylamide. Neuro-psychopharmacology 17:202-204
60. Javitt DC, Zukin SR (1991): Recent advances in the phencyclidine model of schizophrenia [see comments]. Am J Psychiat 148:1301-1308
61. Javitt DC, Zylberman I, Zukin SR, Heresco-Levy U, Lindenmayer JP (1994): Amelioration of negative symptoms in schizophrenia by glycine. Am J Psychiat 151:1234-1236
62. Jentsch JD, Elsworth JD, Redmond DE, Jr., Roth RH (1997): Phencyclidine increases forebrain monoamine metabo-lism in rats and monkeys: Modulation by the isomers ofHA966. J Neurosci 17:1769-1775
63. Jentsch JD, Roth RH (1999): The neuropsychopharmacology of phencyclidine: from NMDA receptor hypofunction tothe dopamine hypothesis of schizophrenia. Neuropsychopharmacology 20:201-225
64. Karper LP, Freeman GK, Grillon C, Morgan CA, Char-ney DS, Krystal JH (1996): Preliminary evidence of an association between sensorimotor gating and distractibil-ity in psychosis. J NeuropsychiatClinNeurosci 8:60-66
65. Keefe RS, Frescka E, Apter SH, Davidson M, Macaluso JM, Hirschowitz J, Davis KL (1996): Clinical characteristicsof Kraepelinian schizophrenia: Replication and extension of previous findings. Am J Psychiat 153:806-811
66. Kegeles LS, Zea-Ponce Y, Abi-Dargham A, Mann JJ, Laruelle M (1999): Ketamine modulation of amphetamine-induced striatal dopamine release in humans. BiolPsychiat 45:20S
67. Kehne JH, Baron BM, Carr AA, Chaney SF, Elands J, Feldman DJ, Frank RA, van Giersbergen PL, McCloskey TC, Johnson MP, McCarty DR, Poirot M, Senyah Y, SiegelBW, Widmaier C (1996): Preclinical characterization ofthe potential of the putative atypical antipsychotic MDL100, 907 as a potent 5-HT2A antagonist with a favorableCNS safety profile. J PharmacolExpTher 277:968-981
68. Keith VA, Mansbach RS, Geyer MA (1991): Failure of haloperidol to block the effects of phencyclidine and dizo-cilpine on prepulse inhibition of startle. BiolPsychiat 30:557-566
69. Komuro H, Rakic P (1993): Modulation of neuronal migration by NMDA receptors. Science 260:95-97
70. Konig P, Chwatal K, Havelec L, Riedl F, Schubert H, Schultes H (1996): Amantadine versus biperiden: Adouble-blind study of treatment efficacy in neurolepticextrapyramidal movement disorders. Neuropsychobiol-ogy 33:80-84
71. Krystal JH, Abi-Dargham A, Laruelle M, Moghaddam B (1999a): Pharmacologic model psychoses. In CharneyDS, Nestler E, Bunney BS (ed), Neurobiology of MentalIllness. New York: Oxford University Press, pp 214-224
72. Krystal JH, Belger A, Abi-Saab W, Moghaddam B, Charney DS, Anand A, Madonick S, D’Souza DC (1999b):Glutamatergic contributions to cognitive dysfunction inschizophrenia. In Harvey PD, Sharma T (eds), CognitiveFunctioning in Schizophrenia. London, Oxford Univer-sity Press
73. Krystal JH, Belger A, Kirino E, Gore J, McCarthy G (1998a): Ketamine effects on the cortical processing of novelty inhumans assessed with FMRI. SocNeurosciAbst 24:259
74. Krystal JH, Bennett A, Abi-Saab D, Belger A, Karper LP, D’Souza DC, Lipschitz D, Abi-Dargham A, Charney DS(1999c): Dissociation of ketamine effects on rule acquisi-tion and rule implementation: Possible relevance toNMDA receptor contributions to executive cognitivefunctions. BiolPsychiat, in press
75. Krystal JH, Bennett A, Bremner JD, Southwick S, Charney DS (1995): Toward a cognitive neuroscience of dissocia-tion and altered memory functions in post-traumaticstress disorder. In Friedman MJ, Charney DS, DeutchAY (eds), Neurobiological and Clinical Consequences ofStress: From Normal Adaptation to PTSD. New York:Raven, pp 239-269
76. Krystal JH, D’Souza DC, Karper LP, Bennett A, Abi-Dargham A, Abi-Saab D, Bowers MB Jr., Jatlow P, Heninger GR, Charney DS (1999d): Interactive effects ofsubanesthetic ketamine and haloperidol. Psychophar-macology 145:193-204
77. Krystal JH, D’Souza DC, Petrakis IL, Belger A, Berman R, Charney DS, Abi-Saab W, Madonick S (1999e): NMDAagonists and antagonists as probes of glutamatergic
78. dysfunction and pharmacotherapies for neuropsychiat-ric disorders. Harv Rev Psychiat 7:125-133
79. Krystal JH, Karper LP, Bennett A, D’Souza DC, Abi-Dargham A, Morrissey K, Abi-Saab D, Bremner JD, Bowers MB Jr., Suckow RF, Stetson P, Heninger GR, Charney DS (1998b): Interactive effects of subanestheticketamine and subhypnoticlorazepam in humans. Psy-chopharmacology 135:213-229
80. Krystal JH, Karper LP, D’Souza DC, Belger A, Abi-Saab D, White J, Charney DS, Grillon C (1999f): Disruption ofhuman sensorimotor gating by subanesthetic ketamine.in preparation
81. Krystal JH, Karper LP, Seibyl JP, Freeman GK, Delaney R, Bremner JD, Heninger GR, Bowers MB Jr., Charney DS(1994a): Subanesthetic effects of the noncompetitiveNMDA antagonist, ketamine, in humans. Psychotomi-metic, perceptual, cognitive, and neuroendocrineresponses. Arch Gen Psychiat 51:199-214
82. Krystal JH, Moghaddam B, Breier A, Goldman-Rakic P, McElvey J (1998c): Glutamate, dopamine, the frontalcortex, and schizophrenia. BiolPsychiat 43:60S
83. Krystal JH, Webb E, Cooney N, Kranzler HR, Charney DS (1994b): Specificity of ethanol-like effects elicited byserotonergic and noradrenergic mechanisms. Arch GenPsychiat 51:898-911
84. Kurumaji A, McCulloch J (1990): Effects of unilateral intrahip-pocampal injection of MK-801 upon local cerebral glucose utilisation in conscious rats. Brain Res 518:342-346
85. Lahti AC, Holcomb HH, Medoff DR, Tamminga CA (1995a): Ketamine activates psychosis and alters limbic bloodflow in schizophrenia. Neuroreport 6:869-872
86. Lahti AC, Koffel B, LaPorte D, Tamminga CA (1995b): Sub-anesthetic doses of ketamine stimulate psychosis in schizophrenia. Neuropsychopharmacology 13:9-19
87. Laruelle M, Abi-Dargham A, van Dyck CH, Gil R, D’Souza CD, Erdos J, McCance E, Rosenblatt W, Fingado C, Zoghbi SS, Baldwin RM, Seibyl JP, Krystal JH, CharneyDS, Innis RB (1996): Single photon emission computer-ized tomography imaging of amphetamine-induceddopamine release in drug-free schizophrenic subjects.Proc Nat AcadSci USA 93:9235-9240
88. Leiderman E, Zylberman I, Zukin SR, Cooper TB, Javitt DC (1996): Preliminary investigation of high-dose oral glycine on serum levels and negative symptoms in schizo-phrenia: An open-label trial [see comments]. BiolPsychiat 39:213-215
89. Lejeune F, Gobert A, Rivet JM, Millan MJ (1994): Blockade of transmission at NMDA receptors facilitates the electri-cal and synthetic activity of ascending serotoninergicneurones. Brain Res 656:427-431
90. Levesque D, Diaz D, Pilon C, Martres M-P, Giros B, Souil E, Schott D, Morgat J-L, Schwartz J-C, Sokoloff P (1992):Identification, characterization, and localization of thedopamine D3receptor in rat brain using 7-[3H]hydroxy-N, N-di-n-propyl-2-aminotetralin. ProcNatlAcadSciUSA 89:8155-8159
91. Liddle PF, Morris DL (1991): Schizophrenic syndromes and frontal lobe performance. Br J Psychiat 158:340-345
92. Lieberman JA, Kane JM, Alvir J (1987a): Provocative tests with psychostimulant drugs in schizophrenia. Psycho-pharmacology 91:415-433
93. Lindefors N, Ballarin M, Ernfors P, Falkenberg T, Persson H (1992): Stimulation of glutamate receptors increasesexpression of brain-derived neurotrophic factor mRNAin rat hippocampus. Ann NY AcadSci 648:296-299
94. Lindefors N, Barati S, O’Connor WT (1997): Differential effects of single and repeated ketamine administrationon dopamine, serotonin, and GABA transmission in ratmedial prefrontal cortex. Brain Res 759:205-212
95. Lipschitz DS, D’Souza DC, White JA, Charney DS, Krystal JH (1997): Clozapine blockade of ketamine effects inhealthy subjects. BiolPsychiat 41:23S
96. Lipton SA, Kater SB (1989): Neurotransmitter regulation of neuronal outgrowth, plasticity and survival. TINS12:265-270
97. Lisman JE, Fellous JM, Wang XJ (1998): A role for NMDA-receptor channels in working memory. Nat Neurosci 1:273-276
98. Lubke J, Markram H, Frotscher M, Sakmann B (1996): Fre-quency and dendritic distribution of autapsesestab-lished by layer 5 pyramidal neurons in the developing rat neocortex: Comparison with synaptic innervation ofadjacent neurons of the same class. J Neurosci 16:3209-3218
99. Luby ED, Cohen BD, Rosenbaum G, Gottlieb JS, Kelley R (1959): Study of a new schizophrenomimetic drug—Ser-nyl. Arch NeurolPsychiat 81:363-369
100. Madison DV, Malenka RC, Nicoll RA (1991): Mechanisms underlying long-term potentiation of synaptic transmission. Ann Rev Neurosci 14:379-397
101. Magistretti PJ, Pellerin L (1997): Metabolic coupling during activation. A cellular view.AdvExp Med Biol 413:161-166
102. Malhotra AK, Adler CM, Kennison SD, Elman I, Pickar D, Breier A (1997): Clozapine blunts N-methyl-D-aspartateantagonist-induced psychosis: A study with ketamine.BiolPsychiat 42:664-668
103. Malhotra AK, Pinals DA, Weingartner H, Sirocco K, Missar CD, Pickar D, Breier A (1996): NMDA receptor functionand human cognition: The effects of ketamine in healthyvolunteers. Neuropsychopharmacology 14:301-307
104. Marini AM, Rabin SJ, Lipsky RH, Mocchetti I (1998): Activ-ity-dependent release of brain-derived neurotrophic factor underlies the neuroprotective effect of N-methyl-D-aspartate. J BiolChem 273:29394-29399
105. Martin P, Waters N, Carlsson A, Carlsson ML (1997): The apparent antipsychotic action of the 5-HT2a receptorantagonist M100907 in a mouse model of schizophreniais counteracted by ritanserin. J Neural Transm 104:561-564
106. Martin P, Waters N, Schmidt CJ, Carlsson A, Carlsson ML (1998): Rodent data and general hypothesis: Antipsy-chotic action exerted through 5-HT2A receptor antago-nism is dependent on increased serotonergic tone. JNeural Transm 105:365-396
107. Meltzer HY (1997): Treatment-resistant schizophrenia—The role of clozapine. Curr Med Res Opin 14:1-20
108. Miller CH, Hummer M, Pycha R, Fleischhacker WW (1992): The effect of ritanserin on treatment-resistant neurolep-tic-induced akathisia: Case reports. ProgNeuropsycho-pharmacolBiolPsychiat 16:247-251
109. Moghaddam B, Adams B, Verma A, Daly D (1997): Activa-tion of glutamatergic neurotransmission by ketamine: A novel step in the pathway from NMDA receptor blockade to dopaminergic and cognitive disruptions associated with the prefrontal cortex. J Neurosci 17:2921-2927
110. Moghaddam B, Adams BW (1998): Reversal of phencycli-dine effects by a group II metabotropic glutamate recep-tor agonist in rats. Science 281:1349-1352
111. Nehls DG, Kurumaji A, Park CK, McCulloch J (1988): Differential effects of competitive and noncompetitive N-methyl-D-aspartate antagonists on glucose use in thelimbic system. NeurosciLett 91:204-210
112. Newcomer JW, Farber NB, Jevtovic-Todorovic V, Selke G, Kelly Melson A, Hershey T, Craft S, Olney JW (1999):Ketamine-induced NMDA receptor hypofunction asmodel of memory impairment and psychosis. Neuro-psychopharmacology 20:106-118
113. Offord SJ (1998): M100907, a highly selective 5-HT2A antagonist for treatment of schizophrenia: Early indication of safety and clinical activity in schizophrenic patients.Poster presented at the 21st Collegium InternationalNeuro-Psychopharmacologium (CINP) Congress, Glasgow, Scotland
114. Olney JW, Farber NB (1995a): Glutamate receptor dysfunction and schizophrenia [see comments]. Arch Gen Psychiat 52:998-1007
115. Olney JW, Farber NB (1995b): NMDA antagonists as neuro-therapeutic drugs, psychotogens, neurotoxins, and research tools for studying schizophrenia. Neuropsychopharmacology 13:335-345
116. Oye I, Paulsen O, Maurset A (1992): Effects of ketamine on sensory perception: Evidence for a role of N-methyl-D-aspartate receptors. J PharmacolExpTher 260:1209-1213
117. Patel TR, McCulloch J (1995): AMPA receptor antagonism attenuates MK-801-induced hypermetabolism in theposterior cingulate cortex. Brain Res 686:254-258
118. Raedler TJ, Knable MB, Weinberger DR (1998): Schizophre-nia as a developmental disorder of the cerebral cortex. CurrOpinNeurobiol 8:157-161
119. Rajkowska G, Selemon LD, Goldman-Rakic PS (1998): Neuronal and glial somal size in the prefrontal cortex: A postmortem morphometric study of schizophrenia andHuntington’s disease. Arch Gen Psychiat 55:215-224
120. Rakic P, Bourgeois JP, Goldman-Rakic PS (1994): Synaptic development of the cerebral cortex: Implications forlearning, memory, and mental illness. Prog Brain Res102:227-243
121. Reich DL, Silvay G (1989): Ketamine: An update on the first twenty-five years of clinical experience. Can J Anaesth36:186-197
122. Rothman SM, Olney JW (1987): Excitotoxicity and the NMDA receptor. TINS 10:299-302
123. Schiller J, Schiller Y, Clapham DE (1998): NMDA receptors amplify calcium influx into dendritic spines duringassociative pre- and postsynaptic activation. Nat Neu-rosci 1:114-118
124. Schmidt CJ, Fadayel GM (1996): Regional effects of MK-801 on dopamine release: Effects of competitive NMDA or5-HT2A receptor blockade. J PharmacolExpTher277:1541-1549
125. Segal M (1995): Imaging of calcium variations in living dendritic spines of cultured rat hippocampal neurons. J Physiol 486:283-295
126. Selemon LD, Rajkowska G, Goldman-Rakic PS (1998): Elevated neuronal density in prefrontal area 46 in brains from schizophrenic patients: Application of a three-dimensional, stereologic counting method. J CompNeurol 392:402-412
127. Sibson NR, Dhankhar A, Mason GF, Behar KL, Rothman DL, Shulman RG (1997): In vivo 13C NMR measurements ofcerebral glutamine synthesis as evidence for glutamateglutamine cycling. Proc Nat AcadSci USA 94:2699-2704
128. Sibson NR, Dhankhar A, Mason GF, Rothman DL, Behar KL, Shulman RG (1998): Stoichiometric coupling of brainglucose metabolism and glutamatergic neuronal activ-ity. Proc Nat AcadSci USA 95:316-321
129. Stefani A, Spadoni F, Siniscalchi A, Bernardi G (1996): Lam-otrigine inhibits Ca2+ currents in cortical neurons: Functional implications. Eur J Pharmacol 307:113-116
130. Swerdlow NR, Geyer MA (1998): Using an animal model of deficient sensorimotor gating to study the pathophysi-ology and new treatments of schizophrenia. SchizophrBull 24:285-301
131. Tamminga CA, Tanimoto K, Kuo S, Chase TN, Contreras PC, Rice KC, Jackson AE, O’Donohue TL (1987): PCP-induced alterations in cerebral glucose utilization in ratbrain: Blockade by metaphit, a PCP-receptor-acylatingagent. Synapse 1:497-504
132. Tamminga CA, Thaker GK, Buchanan R, Kirkpatrick B, Alphs LD, Chase TN, Carpenter WT (1992): Limbic system abnormalities identified in schizophrenia usingpositron emission tomography with fluorodeoxyglu-cose and neocortical alterations with deficit syndrome.Arch Gen Psychiat 49:522-530
133. Tsai G, Yang P, Chung LC, Lange N, Coyle J (1998): D-serine added to antipsychotics for the treatment of schizophre-nia. BiolPsychiat 44
134. Umbricht D, Vollenweider FX, Javitt D, Schmidt L, Hell D (1999): Effects of ketamine on preattentive and atten-tion-dependent auditory event-related potentials (ERP).Schizophr Res 36:260
135. Van Tol HHM, Bunzow JR, Guan H-C, Sunahara RK, See-man P, Niznik HB, Civelli O (1991): Cloning of the gene for a human dopamine D4receptor with high affinityfor the antipsychotic clozapine. Nature 350:610-614
136. Varty GB, Bakshi VP, Geyer MA (1999): M100907, a serotonin 5-HT2A receptor antagonist and putative antipsy-chotic blocks dizocilpine-induced prepulse inhibition deficits in Sprague-Dawley and Wistar rats. Neuropsy-chopharmacology 29:311-321
137. Verma A, Moghaddam B (1996): NMDA receptor antago-nists impair prefrontal cortex function as assessed via spatial delayed alternation performance in rats: modulation by dopamine. J Neurosci 16:373-379
138. Waldmeier PC, Martin P, Stocklin K, Portet C, Schmutz M (1996): Effect of carbamazepine, oxcarbazepine, andlamotrigine on the increase in extracellular glutamateelicited by veratridine in rat cortex and striatum. Nau-nyn-Schmiedebergs Arch Pharmacol 354:164-172
139. Wang SJ, Huang CC, Hsu KS, Tsai JJ, Gean PW (1996): Inhibition of N-type calcium currents by lamotrigine in rat amygdalarneurones. Neuroreport 7:3037-3040
140. Wang XJ, Buzsaki G (1996): Gamma oscillation by synaptic inhibition in a hippocampal interneuronal networkmodel. J Neurosci 16:6402-6413
141. Weinberger DR, Berman KF (1996): Prefrontal function in schizophrenia: Confounds and controversies. PhilosophTrans Roy SocLond—Series B: BiologSci 351:1495-1503
142. White PF, Way WL, Trevor AJ (1982): Ketamine—Itsphar-macology and therapeutic uses. Anesthesiology 56:119-136
143. Wiesel FA, Nordstrom AL, Farde L, Eriksson B (1994): An open clinical and biochemical study of ritanserin inacute patients with schizophrenia. Psychopharmacol-ogy 114:31-38
144. Williams GV, Goldman-Rakic PS (1995): Modulation of memory fields by dopamine D1 receptors in prefrontalcortex [see comments]. Nature 376:572-575
145. Wilson FA, O’Scalaidhe SP, Goldman-Rakic PS (1994): Func-tional synergism between putative gamma-aminobu-tyrate-containing neurons and pyramidal neurons in prefrontal cortex. Proc Nat AcadSci USA 91:4009-4013
146. Woo TU, Whitehead RE, Melchitzky DS, Lewis DA (1998): A subclass of prefrontal gamma-aminobutyric acid axonterminals are selectively altered in schizophrenia. ProcNat AcadSci USA 95:5341-5346
147. Yuste R, Majewska A, Cash SS, Denk W (1999): Mechanisms of calcium influx into hippocampal spines: Heterogene-ity among spines, coincidence detection by NMDAreceptors, and optical quantal analysis. J Neurosci196:1976-1987
148. Zukin SR, Zukin RS (1979): Specific [3H]phencyclidine bind-ing in rat central nervous system. Proc Nat AcadSci USA 76:5372-5376